Nancy L. Lewis Appointed as New Chief Scientific Officer of NCCN
On April 9, 2026, the National Comprehensive Cancer Network (NCCN) made a significant announcement regarding the appointment of Dr. Nancy L. Lewis as its new Chief Scientific Officer (CSO). Dr. Lewis, a distinguished biomedical researcher specializing in the clinical trials of solid tumors and hematological malignancies, is an established leader in medical research, bringing a wealth of experience to the role. She previously served as the head of a clinical program at Novartis Pharmaceuticals and has spent several years working as an assistant professor at renowned academic oncology centers. With degrees from Penn State University, Temple University School of Medicine, and Rutgers University, Dr. Lewis has also completed her residency at the University of Rochester and a fellowship at Fox Chase Cancer Center, one of NCCN's founding institutions.
The announcement was made by Dr. Crystal S. Denlinger, the outgoing CSO who has transitioned to the role of CEO at NCCN. "We are entering a pivotal era for cancer research with numerous successes to build upon, yet we have much work ahead of us. Dr. Lewis is the perfect candidate to oversee the innovative research and knowledge discovery that will improve the lives of cancer patients," commented Denlinger.
Dr. Lewis’s appointment comes at a time when the need for impactful research in cancer treatment is more crucial than ever. She will now oversee various essential aspects of NCCN's oncology research program (ORP), alongside leading initiatives such as the NCCN Clinical Practice Guidelines in Oncology, commonly recognized as NCCN Guidelines®, and the patient-oriented NCCN Guidelines for Patients®. Her responsibilities also include the oversight of the NCCN Biomarkers Compendium®, NCCN Radiotherapy Compendium™, and the NCCN Imaging Appropriate Use Criteria™. Furthermore, Dr. Lewis will assist in the NCCN's continuing medical education programs and its global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its remarkable legacy of supporting high-quality cancer care," stated Dr. Lewis. "I look forward to collaborating with the outstanding NCCN team to address emerging challenges and promote innovative solutions that enhance the lives of patients worldwide."
Dr. Lewis will commence her new role in May 2026, succeeding Dr. Denlinger in a position pivotal to advancing NCCN's mission as a non-profit alliance of leading cancer centers dedicated to patient care, research, and education.
The NCCN is at the forefront of defining and promoting high-quality, effective, equitable, and accessible cancer care. This commitment to excellence is reflected in their oncology clinical practice guidelines, which provide evidence-based treatment recommendations and are recognized as a trusted standard in cancer treatment direction and policy. The guidelines are the most comprehensive resources available for clinical practice in medicine today. Additionally, NCCN's patient guidelines empower patients and caregivers with expert information related to cancer treatment, supported by the NCCN Foundation.
In the backdrop of global health issues, the work of NCCN emphasizes the importance of equitable and effective cancer treatment while participating in further education, global collaborations, and groundbreaking cancer research. Dr. Lewis’s leadership will be integral in ensuring that NCCN continues its trajectory of innovation and excellence in cancer care and research.
More information about the NCCN can be found at their official website, NCCN.org.
The announcement was made by Dr. Crystal S. Denlinger, the outgoing CSO who has transitioned to the role of CEO at NCCN. "We are entering a pivotal era for cancer research with numerous successes to build upon, yet we have much work ahead of us. Dr. Lewis is the perfect candidate to oversee the innovative research and knowledge discovery that will improve the lives of cancer patients," commented Denlinger.
Dr. Lewis’s appointment comes at a time when the need for impactful research in cancer treatment is more crucial than ever. She will now oversee various essential aspects of NCCN's oncology research program (ORP), alongside leading initiatives such as the NCCN Clinical Practice Guidelines in Oncology, commonly recognized as NCCN Guidelines®, and the patient-oriented NCCN Guidelines for Patients®. Her responsibilities also include the oversight of the NCCN Biomarkers Compendium®, NCCN Radiotherapy Compendium™, and the NCCN Imaging Appropriate Use Criteria™. Furthermore, Dr. Lewis will assist in the NCCN's continuing medical education programs and its global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its remarkable legacy of supporting high-quality cancer care," stated Dr. Lewis. "I look forward to collaborating with the outstanding NCCN team to address emerging challenges and promote innovative solutions that enhance the lives of patients worldwide."
Dr. Lewis will commence her new role in May 2026, succeeding Dr. Denlinger in a position pivotal to advancing NCCN's mission as a non-profit alliance of leading cancer centers dedicated to patient care, research, and education.
The NCCN is at the forefront of defining and promoting high-quality, effective, equitable, and accessible cancer care. This commitment to excellence is reflected in their oncology clinical practice guidelines, which provide evidence-based treatment recommendations and are recognized as a trusted standard in cancer treatment direction and policy. The guidelines are the most comprehensive resources available for clinical practice in medicine today. Additionally, NCCN's patient guidelines empower patients and caregivers with expert information related to cancer treatment, supported by the NCCN Foundation.
In the backdrop of global health issues, the work of NCCN emphasizes the importance of equitable and effective cancer treatment while participating in further education, global collaborations, and groundbreaking cancer research. Dr. Lewis’s leadership will be integral in ensuring that NCCN continues its trajectory of innovation and excellence in cancer care and research.
More information about the NCCN can be found at their official website, NCCN.org.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.